FDA finalizes validation guidance for emergency pathogen tests; first BD OneFlow lymphoma tests cleared; NKF report favors urinary albumin

A laboratory microscope with binocular eyepieces, a glass slide on its stage holding a softly stained tissue section.

The Food and Drug Administration (FDA) issued final guidance on Nov. 9 on validating in vitro diagnostic tests for emerging pathogens during a Section 564 declared emergency, replacing a January 2025 draft.

Waters announced 510(k) clearance of two BD OneFlow flow cytometry tests for B-cell lymphoma, and a National Kidney Foundation (NKF) workshop report said urinary albumin should generally be preferred over total protein.

  • FDA Nov 9, 2026
    The Food and Drug Administration (FDA) issued final guidance on Nov. 9 on validating in vitro diagnostic devices for emerging pathogens submitted for emergency use authorization or offered under an enforcement discretion policy during a Section 564 declared emergency, following a draft released Jan. 7, 2025. The final guidance reduces the number of analytical tests developers must conduct from 15 to five, according to RAPS. Early in an outbreak, at least 30 positive and 30 negative specimens from the intended use population are typically adequate, according to Clinical Lab Products. Serology and antibody tests are outside its scope.
  • FDA Nov 10, 2026
    Waters said the BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test received Food and Drug Administration (FDA) 510(k) clearance, the first from the BD OneFlow portfolio, as a standardized, ready-to-use flow cytometry solution that aids identification and diagnosis of B-cell non-Hodgkin lymphoma, including chronic lymphocytic leukemia (CLL). The company reported 96.3% sensitivity and 98.2% specificity for identifying CLL in an internal clinical study. The tests are available for preorder, with U.S. commercial availability expected in spring 2027.
  • Guidelines Nov 14, 2026
    A report of the 2025 Proteinuria-Albuminuria Workshop sponsored by the National Kidney Foundation, published Nov. 14 in the American Journal of Kidney Diseases, said measurement of urinary albumin concentration should in general be preferred over total urinary protein. The report said urinary albumin assays are expected to be internationally standardized beginning in 2027.

The weekly innovation roundup for pathology, published every Sunday for the week before; every item links to its sources. Latest pathology news · All specialties

Latest news

Tagged pathology, from the daily briefing

  1. National Kidney Foundation workshop says measuring urine albumin is generally preferred over total urine protein
  2. Broad genomic sequencing before first-line therapy tied to longer survival than focused testing in advanced lung cancer
  3. Consensus guideline sets standards for measurable residual disease testing in acute lymphoblastic leukemia

See all the latest news